New Edge Advisors, LLC Vertex Pharmaceuticals Inc Transaction History

New Edge Advisors, LLC

$15 Billion
Q3 2024

A detailed history of New Edge Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, New Edge Advisors, LLC holds 11,357 shares of VRTX stock, worth $5.3 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

11,357

Previous 13,632 16.69%

Holding current value

$5.3 Million

Previous $6.39 Million 17.34%

% of portfolio

0.04%

Previous 0.05%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $1.05 Million - $1.15 Million	-2,275 Reduced 16.69%	11,357 $5.28 Million
Q2 2024 Aug 15, 2024	BUY	$392.81 - $485.53 $278,502 - $344,240	709 Added 5.49%	13,632 $6.39 Million
Q1 2024 May 14, 2024	BUY	$407.69 - $446.08 $1.07 Million - $1.17 Million	2,619 Added 25.42%	12,923 $5.4 Million
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $222,950 - $266,942	650 Added 6.73%	10,304 $4.19 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $381,467 - $408,854	1,128 Added 13.23%	9,654 $3.36 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $953,950 - $1.07 Million	3,034 Added 55.24%	8,526 $3 Million
Q1 2023 May 12, 2023	SELL	$283.23 - $323.1 $74,206 - $84,652	-262 Reduced 4.55%	5,492 $1.73 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $78,584 - $88,407	-275 Reduced 4.56%	5,754 $1.66 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $370,765 - $413,687	1,354 Added 28.96%	6,029 $1.75 Million
Q2 2022 Aug 09, 2022	BUY	$234.96 - $292.55 $1.1 Million - $1.37 Million	4,675 New	4,675 $1.32 Million
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $855,345 - $1.01 Million	-3,863 Closed	0 $0
Q4 2021 Feb 17, 2022	BUY	$177.01 - $223.45 $402,874 - $508,572	2,276 Added 143.42%	3,863 $848,000
Q3 2021 Oct 29, 2021	SELL	$181.39 - $202.99 $55,323 - $61,911	-305 Reduced 16.12%	1,587 $288,000
Q2 2021 Jul 22, 2021	BUY	$187.49 - $221.1 $100,119 - $118,067	534 Added 39.32%	1,892 $381,000
Q1 2021 Apr 26, 2021	SELL	$207.02 - $241.31 $192,735 - $224,659	-931 Reduced 40.67%	1,358 $292,000
Q4 2020 Jan 27, 2021	SELL	$207.01 - $276.09 $2.77 Million - $3.69 Million	-13,367 Reduced 85.38%	2,289 $541,000
Q3 2020 Nov 03, 2020	BUY	$255.65 - $303.1 $3.16 Million - $3.75 Million	12,370 Added 376.45%	15,656 $4.26 Million
Q2 2020 Jul 29, 2020	BUY	$225.48 - $295.8 $342,729 - $449,616	1,520 Added 86.07%	3,286 $954,000
Q1 2020 May 04, 2020	BUY	$199.77 - $247.81 $158,617 - $196,761	794 Added 81.69%	1,766 $420,000
Q4 2019 Jan 31, 2020	BUY	$166.71 - $223.91 $162,042 - $217,640	972 New	972 $212,000
Q2 2019 Aug 05, 2019	SELL	$164.61 - $190.37 $210,700 - $243,673	-1,280 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $209,574 - $249,216	1,280 New	1,280 $235,000
Q1 2019 May 09, 2019	SELL	$163.73 - $194.7 $204,662 - $243,375	-1,250 Closed	0 $0
Q4 2018 Jan 29, 2019	BUY	$151.91 - $192.21 $189,887 - $240,262	1,250 New	1,250 $207,000
Q3 2017 Nov 13, 2017	SELL	$148.13 - $162.24 $16,442 - $18,008	-111 Closed	0 $0
Q2 2017 Aug 16, 2017	BUY	N/A	111	111 $0

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.

Account

New Edge Advisors, LLC Vertex Pharmaceuticals Inc Transaction History